

OMTN, Volume 12

Supplemental Information

uc.454 Inhibited Growth by Targeting Heat

Shock Protein Family A Member 12B

in Non-Small-Cell Lung Cancer

Jun Zhou, Chenghai Wang, Weijuan Gong, Yandan Wu, Huimin Xue, Zewei Jiang, and Minhua Shi

Table S1. Sequence of primers and siRNA.

Gene Name	Forward(5'-3')	Reverse (5'-3')
TUCR.454	TAAAGACAGGATGGCTCGAGC	AGTGAACCTACCTCGGTAGTTCC
si- TUCR.454-1	GAUGGCUCGAGCAGGGGCCAA	UUGGCCCCUGCUCGAGCCAUC
si- TUCR.454-2	CCAUGAUCACGGCAUCGGGAA	UUCCCGAUGCCGUGAUCAUGG
si- TUCR.454-3	TAGTTCACTATTTGACAGCTTAA	UUAAGCUGUCAAAUAGUGAACUA
HSPA12B	CACGGATCTCACCTTGAAGA	GACACTAGTCCAGCCAGGTA
si- HSPA12B 1	CCACUGAUCGUUACCUUGAA	UUCAAGGUAAGAUCAGUGG
si- HSPA12B -2	CUUCAUUGACUUCUACCGCAA	UUGCGGUAGAAGUCAAUGAAG
U6	CAGAGCCCATCGCTGCCAGAGAA	TTCACGAATTTGCGTGTCAT
GAPDH	GAAGGTGAAGGTCGGAGTC	GAAGATGGTGATGGGATTTC

Figure S1




Table S2: Characteristics of the study subjects with non-small cell lung cancer (NSCLC)

Clinicopathologic features	Number	Percentage (%)
Age (years)		
<60	33	33.7
≥60	65	66.3
Tumor size (cm)		
<5	28	28.6
≥5	70	71.4
Tumor site		
central	55	56.1
peripheral	43	43.9
Pathological type		
squamous-cell carcinoma	54	55.1
adenocarcinoma	44	44.9
Pathological grade		
I	19	19.4
II	9	9.2
III	70	71.4
Tumor invasive depth		
T1+T2	52	53.1
T3+T4	46	46.9
lymph node metastasis		
negative	36	36.7
positive	62	63.3

Distant metastasis

M0 41 41.8

M1 57 58.2

Tumor stage

I 11 11.2

II 26 26.5

III 31 31.6

IV 30 30.7

Survival time

≥5 years 52 53.1

<5 years 42 42.9

unknown 4 4.0
